BiotechTube
Home/IGM Biosciences/Fred Schwarzer
FS

Fred Schwarzer

Chief Executive Officer

IGM Biosciences

Therapeutic Areas

OncologyAutoimmune & Inflammatory Diseases

IGM Biosciences Pipeline

DrugIndicationPhase
Imvotamab (IGM-2323)Relapsed/Refractory Non-Hodgkin's Lymphoma, DLBCL, Follicular LymphomaPhase 2
Aplitabart (IGM-8444)Solid Tumors (Colorectal, Ovarian, etc.)Phase 1/2
IGM-7354Autoimmune & Inflammatory Diseases (via IL-6R)Phase 1
IGM-2644Multiple MyelomaPreclinical
IGM-2537IgE-Mediated AllergiesPreclinical

Leadership Team at IGM Biosciences

BK
Bruce Keyt, Ph.D.
Chief Scientific Officer & Head of Research
JM
Joel Martin, Ph.D.
Senior Vice President, Manufacturing & Process Sciences
BS
Bryan Sakamoto, M.D., Ph.D.
Senior Vice President, Clinical Development
DC
Daniel Chen, M.D., Ph.D.
Former Chief Medical Officer
BC
Bruce Carter, Ph.D.
Board Member
JB
James Breitmeyer, M.D., Ph.D.
Board Member
View full IGM Biosciences profile